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Abstract
Multidrug resistance in Gram-positive pathogens emerged as a major therapeutic challenge over two decades ago. The worldwide
spread of methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci and other resistant Gram-positive patho-
gens had a major impact on antibiotic policies, and prompted the discovery and development of new antibiotics to combat difﬁcult-to-
treat infections caused by such pathogens. Several new antibiotics active against multidrug-resistant Gram-positive pathogens have
recently been introduced into clinical practice, and the antibiotic pipeline contains additional anti-Gram-positive drugs at an advanced
stage of development, including new glycopeptides (dalbavancin, oritavancin, and telavancin), new anti-MRSA b-lactams (ceftobiprole),
and new diaminopyrimidines (iclaprim). This article provides a brief overview of these upcoming agents, partially based on the material
presented at the ESCMID Conference entitled ‘Fighting infections due to multidrug-resistant Gram-positives’ (Venice, Italy, 29–31 May
2008) and on the most recent literature.
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Major Resistance Challenges Posed by
Gram-Positive Pathogens and Overview of
the Anti-Gram-Positive Pipeline
Antibiotic resistance has become a major public health prob-
lem on a global scale. Resistance issues are no longer con-
ﬁned to some pathogenic species and to certain healthcare
settings, but affect virtually all major bacterial pathogens and
all types of epidemiological settings (acute-care hospitals,
long-term-care facilities, community), although considerable
variability in the epidemiology of resistance can be observed
in different geographical and epidemiological settings [1,2 and
http://www.rivm.nl/earss/].
In Gram-positive pathogens, multidrug resistance emerged
as a major therapeutic challenge in the 1980s [3]. The world-
wide spread of methicillin-resistant Staphylococcus aureus
(MRSA), glycopeptide-resistant enterococci (GRE) and pneu-
mococci resistant to penicillin and macrolides, and the more
recent emergence of vancomycin-intermediate S. aureus
(VISA) and vancomycin-resistant S. aureus (VRSA) strains,
had a major impact on antibiotic policies and prompted an
active reaction from the pharmaceutical industry concerning
the discovery and development of new antibiotics to combat
these strains. Consequently, several new antibiotics active
against multidrug-resistant (MDR) Gram-positive pathogens
have recently been introduced into clinical practice (e.g.
quinupristin–dalfopristin, linezolid, daptomycin, and tigecy-
cline), and the antibiotic pipeline contains additional anti-
Gram-positive drugs at an advanced stage of development,
including new glycopeptides (e.g. dalbavancin, oritavancin,
and telavancin), new anti-MRSA b-lactams (e.g. ceftobiprole
and ceftaroline), and new diaminopyrimidines (e.g. iclaprim).
The aim of this review is to provide a brief summary of
these upcoming antibiotics active against MDR Gram-positive
pathogens, partially based on the the material presented at
the ESCMID Conference entitled ‘Fighting infections due to
multidrug-resistant Gram-positives’ (Venice, Italy, 29–31
May 2008) by leading representatives of pharmaceutical
companies, and on the most recent literature.
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The New Glycopeptides for MDR
Gram-Positive Pathogens
Exploitation of the scaffold of the ﬁrst-generation glycopep-
tides, vancomycin and teicoplanin, has proved a successful
strategy to obtain new glycopeptides with modiﬁed pharma-
cokinetic and pharmacodynamic properties and with
enhanced activity against MDR Gram-positive pathogens.
Three such derivatives are well advanced in the pipeline, and
introduction into clinical practice is expected in the near
future.
Dalbavancin
Dalbavancin (Pﬁzer, New York, USA) is a semisynthetic lipo-
glycopeptide derived from a teicoplanin analog (Fig. 1), with
a mechanism of action similar to that of older glycopeptides
[4]. The presence of the lipophilic side chain improves the D-
Ala-D-Ala target recognition, and results in signiﬁcantly lower
MICs for staphylococci (including MRSA strains), enterococci,
and streptococci, as compared to older glycopeptides.
Potent in vitro activity is retained against VISA strains and
also against VanB enterococci, but whether the latter feature
translates into clinical efﬁcacy remains to be conﬁrmed. On
the other hand, dalbavancin is poorly active against vancomy-
cin-resistant organisms with a VanA resistance mechanism
(Table 1). Against staphylococci (including MRSA), dalbavan-
cin exhibits potent bactericidal activity, with bactericidal
rates that are superior to those of the older glycopeptides
[5,6]. A low potential for in vitro selection of resistance has
been documented [5] in preclinical and clinical studies (Gold-
stein et al., 45th ICAAC, 2005, Abstract L-1577).
The presence of the long lipophilic side chain in the dalba-
vancin molecule is most probably the reason for its very long
half-life of approximately 8 days [7]; this allows for the pro-
posed once-weekly regimen (1000 mg on day 1 and 500 mg
after 1 week), which could be very convenient and could
allow for earlier patient discharge. The more lipophilic struc-
ture also accounts for an intracellular penetration that is
superior to that of older glycopeptides (Bulgheroni et al.,
44th ICAAC, 2004, Abstract A-1490). Approximately 40% of
the dose is excreted unmodiﬁed in the urine, and 20% is
excreted unchanged in stools. Dose adjustment may not be
necessary in subjects with impaired liver function, or in
patients with mild to moderate renal impairment (Dowell,
ISICEM 2008, Poster P026). Investigation concerning the
FIG. 1. Structures of the new anti-Gram-positive compounds.
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effect of dalbavancin administration on the gut microbiota of
healthy subjects showed that it did not select for Clostridium
difﬁcile, or result in changes of the major anaerobic compo-
nents or the selection of dalbavancin-resistant aerobic or
anaerobic bacteria [8].
The clinical efﬁcacy of dalbavancin has been investigated in
patients with complicated skin and skin structure infections
(cSSSIs) and with catheter-related bloodstream infections. In
a large phase III trial involving patients with cSSSIs, including
surgical site infections, dalbavancin proved at least as effec-
tive as linezolid, as judged by clinical cure rates and micro-
biological success at the test of cure (14 ± 2 days after the
end of treatment). Notably, the MRSA subset accounted for
approximately half of the randomized patients [9]. In a small
non-blinded trial involving patients with catheter-related
bloodstream infections caused by Gram-positive pathogens, a
superior clinical response was observed in patients receiving
dalbavancin than in those receiving standard vancomycin
treatment [10]. Safety and tolerability proﬁles were overall
similar to those of comparators. An additional phase III clini-
cal trial involving patients with cSSSIs is planned to complete
the regulatory submission to the EMEA and the FDA.
Oritavancin
Oritavancin (Targanta Therapeutics, Cambridge, MA, USA)
(Fig. 1) is a semisynthetic lipoglycopeptide derived from the
natural compound chloroeremomycin. The differences with
respect to older glycopeptides result in substantial improve-
ments of the pharmacodynamic properties (mediated, at least
in part, by dimerization upon target binding), which include
the ability to bind depsipeptides (such as D-Ala-D-Lac, pres-
ent in VanA-type resistant organisms) and to exert an addi-
tional mechanism of action that consists of membrane
disruption [11] (McKay et al., 46th ICAAC, 2006, Abstract
C1-682; Arhin et al., 47th ICAAC, 2007, Abstract C1-1471;
Wang et al., 47th ICAAC, 2007, Abstract C1-1474). These
properties reﬂect the microbiological proﬁle of oritavancin,
which shows potent activity against major Gram-positive
pathogens, including MRSA, VISA and most vancomycin-resis-
tant organisms (Table 1), and, unlike the older glycopeptides,
exerts rapid concentration-dependent bacterial killing
(McKay et al., 18th ECCMID, 2008, Abstract P-544). Interest-
ingly, oritavancin is also accumulated intracellularly, and
exhibits bactericidal activity against intracellular small-colony
variants of S. aureus, which are known to be involved in
some persistent infections (e.g. osteomyelits) (Nguyen et al.,
47th ICAAC, 2007, Abstract A-1437; Nguyen et al., 18th
ECCMID, 2008, Abtract P-1059). Oritavancin resistance has
not yet been described in clinical isolates of S. aureus, but
moderate increases in oritavancin MICs can be selected for
in vitro in multistep mutants of VanA and VanB enterococci
[12].
However, in that study, MICs were determined using agar-
based methods, which function poorly for oritavancin; fur-
thermore, susceptibility breakpoints have not yet been set
for oritavancin by either the EMEA or the FDA. Susceptibility
and resistance studies in the presence of 0.002% polysorbate-
80, now recommended by the CLSI for broth microdilution
assays of oritavancin (guideline M100-S18; CLSI, 2008), sug-
gest that the MIC of oritavancin for mutants selected after 20
hours of exposure of S. aureus (including MRSA, VISA, and
VRSA), enterococci (including both VanA and VanB strains of
both Enterococcus faecalis and Enterococcus faecium) and Bacillis
subtilis (surrogate for anthrax) does not exceed 1 mg/L [13;
Targanta Therapeutics, unpublished data].
Preclinical studies in animal models of staphylococcal
and pneumococcal infections showed that AUC/MIC and
Cmax/MIC values are the pharmacokinetic–pharmacodynamic
(PK–PD) parameters predictive of in vivo efﬁcacy, in agree-
ment with the rapid killing effect observed in vitro [14] (Craig
and Andes, 44th ICAAC, 2004, Abtract A-1863; Lehoux
et al., 47th ICAAC, 2007, Abstract A-49). This feature, along
with the long half-life and long-lasting post-antibiotic effect
[15], supports once-daily administration.
The clinical efﬁcacy of oritavancin has been investigated in
cSSSI patients. In phase III studies, oritavancin given at a
TABLE 1. Antimicrobial activity (MIC90 values, mg/L) of the new glycopeptides against Gram-positive pathogens (including
strains with clinically relevant resistance traits)









Dalbavancin 0.06–0.5 0.06–1 1–2 0.06–0.12 ‡32 0.12–1 0.015–0.06
Oritavancin 0.12 0.25 1 0.06 1 0.03a 0.06
Telavancin 0.25 0.50 1 0.25–0.50 4–8 2 0.25
MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; hVISA, heteroresistant vancomycin-intermediate S. aureus; VISA, vancomycin-interme-
diate S. aureus; VRE, vancomycin-resistant enterococci.
Data are from [18,32,33]; Grover et al., 47th ICAAC, 2007, Abstract E-1613; Draghi et al., 47th ICAAC, 2007, Abstract E-1615; Draghi et al., 47th ICAAC, 2007, Abstract
E-1616; Sahm et al., 47th ICAAC, 2007, Abstract E-1617; and Arhin et al., 47th ICAAC, 2007, Abstract D-242. When different MIC90 values have been reported, data are
reported as ranges.
aMaximum MIC value.
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once-daily dose of 200 mg (or 300 mg when body weight
was >110 kg) for up to 7 days, followed by an oral placebo,
was found to be at least as effective as standard vancomycin
treatment followed by oral cephalexin. Notably, effectiveness
of oritavancin-based therapy was achieved following
a shorter duration of therapy (5.3 vs. 10.9 days), and the
percentage of patients who required a discontinuation
because of adverse events was signiﬁcantly lower in the orit-
avancin arm (Giamarellou et al., 43rd ICAAC, 2003, Abstract
L-739a), pointing to a good safety and tolerability proﬁle.
Alternative dosages (including single-dose and two-dose regi-
mens) are under investigation. The results from a recently
completed phase II study involving patients with cSSSI
demonstrate the non-inferiority of oritavancin in both the
single-dose and infrequent-dose regimens as compared to
the once-daily phase III regimen of oritavancin (http://media.
integratir.com/targ/PressReleases/SIMPLIFI_ﬁnal102208.pdf).
Telavancin
Telavancin (Astellas Pharma, Tokyo, Japan) is a semisynthetic
lipoglycopeptide derivative of vancomycin (Fig. 1). As for or-
itavancin, the structural modiﬁcation with respect to vanco-
mycin endows the telavancin molecule with a dual
mechanism of action, targeting the D-Ala-D-Ala depeptide and
the plasma membrane [16] (Lunde et al., 17th ECCMID,
2007, Abstract O256).
This feature results in potent antibacterial activity against
Gram-positive pathogens (including MDR strains) in terms of
MIC values (Table 1), and in rapid concentration-dependent
bactericidal activity that covers MRSA, VISA and VRSA
strains [17]. Activity is also retained against linezolid-non-sus-
ceptible and daptomycin-non-susceptible staphylococcal
strains [18].
Preclinical studies in animal models of infections caused by
Gram-positive pathogens showed that the AUC/MIC ratio
was the best PK–PD parameter with which to predict efﬁ-
cacy [19]. This behaviour, along with a long half-life (7–9 h)
and a long-lasting post-antibiotic effect [20], allows for once-
daily dosing. Telavancin is mostly excreted unchanged in the
urine, and an extension of the dosing intervals is necessary
with creatinine clearance rates lower than 50 mL/min [21].
The clinical efﬁcacy of telavancin has been investigated in
patients with cSSSIs and with hospital-acquired pneumonia,
including ventilator-associated pneumonia. In phase III studies
on cSSSIs, telavancin given at a once-daily dose of 10 mg/kg
(with adjustment for reduced creatinine clearance) was found
to be at least as effective as standard vancomycin, as judged
by clinical cure rates at the test of cure (Corey et al., IDSA
2006, Poster LB-17). The safety proﬁle of telavancin was
similar to that of the comparator, and supports the use of
telavancin for the treatment of cSSSIs (Corey et al., 44th
IDSA, 2006, Abstract LB-17). Similarly, in phase III studies
on hospital-acquired pneumonia/ventilator-associated
pneumonia, telavancin was found to be at least as effective
as the comparator vancomycin (http://www.drugs.com/
clinical_trials/theravance-announces-positive-topline-results-
phase-3-telavancin-hospital-acquired-pneumonia-program-2913.
html), but the results have not been published yet.
The New Anti-MRSA b-lactams
Currently available b-lactams are unable to efﬁciently inhibit
penicillin-binding protein (PBP)2a of methicillin-resistant
staphylococci, and they are not clinically useful for the treat-
ment of infections caused by MRSA and methicillin-resistant
coagulase-negative staphylococci.
Given the overall efﬁcacy and safety of b-lactam antibiot-
ics, an intensive effort has been made to obtain new b-lactam
molecules that are active against methicillin-resistant staphy-
lococci. The most advanced compound in the pipeline is cef-
tobiprole, and ceftaroline and carbapenems with anti-MRSA
activity are at earlier stages of development in the antibiotic
pipeline.
Ceftobiprole
Ceftobiprole (Johnson & Johnson, Langhorne, PA, USA)
(Fig. 1) is the most advanced anti-MRSA cephalosporin in the
pipeline, being already approved for clinical use in some
countries (e.g. Canada and Switzerland).
Unlike the b-lactams that are currently available in clinical
practice, ceftobiprole binds to, and effectively inhibits, PBP2a
of methicillin-resistant staphylococci [22], resulting in MIC
values and bactericidal activity that are overall comparable
with those observed against methicillin-susceptible S. aureus
[23,24]. Activity is also retained against VISA and VRSA [25].
Ceftobiprole activity extends to b-haemolytic streptococci
(Amsler et al., 46th ICAAC, 2006, Abstract E-116) and pneu-
mococci. In fact, because of its good afﬁnity for penicillin-
resistant PBPs of pneumococci, it is the most active cephalo-
sporin against penicillin-resistant pneumococci [26].
Against E. faecalis, ceftobiprole exhibits a behaviour more
similar to that of ampicillin than to that of other cephalospo-
rins, whereas it does not efﬁciently inhibit PBP5 of E. faecium
and is not active against the latter species [24]. Resistance to
ceftobiprole in Gram-positive pathogens was found to be
very difﬁcult to select in vitro after serial passages [25,26]
(Banerjee and Chambers, 47th ICAAC, 2007, Abstract
C1-844), and ceftobiprole-resistant Gram-positive pathogens
were never detected in clinical trials [27,28]. Unlike many
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of the new antibiotics active against MDR Gram-positive
pathogens (such as linezolid, daptomycin, quinupristin–dalfo-
pristin, and the new lipoglycopeptides discussed above),
which show a narrow spectrum of antibacterial activity
against Gram-positive pathogens, ceftobiprole has a very
broad spectrum of activity, including several Gram-negative
pathogens such as the fastidious respiratory pathogen Hae-
mophilus inﬂuenzae, and Moraxella catarrhalis, Enterobacteria-
ceae (except for strains producing extended-spectrum b-
lactamases), Pseudomonas aeruginosa, and non-MDR strains of
Acinetobacter baumannii [23].
Preclinical studies in animal models indicated time-depen-
dent PK–PD behaviour, similar to that of other b-lactams,
with percentage time over the MIC (%T > MIC) being the
PD index for efﬁcacy. Against staphylococci and streptococci,
a %T > MIC breakpoint ‡30% (i.e. similar to that of carba-
penems) has been calculated for efﬁcacy, whereas for Gram-
negative pathogens, the calculated %T > MIC breakpoint is
‡50% (i.e. similar to that of other cephalosporins) [23]. Cef-
tobiprole is administered as a prodrug, ceftobiprole medo-
caril, which is rapidly converted to ceftobiprole in vivo by
plasma esterases. It is primarily excreted unchanged via the
kidney [23].
The clinical efﬁcacy of ceftobiprole has been investigated in
patients with cSSSIs. In phase III studies on cSSSIs, ceftobipro-
le at a dose of 500 mg every 12 h was found to be at least as
effective as standard vancomycin for infections caused by
Gram-positive pathogens, and at a dose of 500 mg every 8 h,
it was found to be at least as effective as standard vancomy-
cin ± ceftazidime for infections caused by both Gram-positive
and Gram-negative pathogens, including diabetic foot infec-
tions, as judged by clinical and microbiological cure rates at
test of cure. No major safety issues have been reported dur-
ing phase III clinical trials with ceftobiprole [27,28].
The New Diaminopyrimidines
Iclaprim (Arpida Pharmaceuticals, Reinach, Switzerland)
(Fig. 1) is the only new diaminopyrimidine derivative in an
advanced stage of clinical development. Iclaprim is a trimeth-
oprim derivative that targets bacterial dihydrofolate reduc-
tase. Owing to its modiﬁed structure, iclaprim retains strong
inhibitory activity against trimethoprim-resistant dihydrofo-
late reductase enzymes [29] (Oefner et al., 18th ECCMID,
2008, Abstract O486), which constitute the most important
mechanism of acquired resistance against trimethoprim in
S. aureus. Iclaprim has potent in vitro activity against S. aureus
(including MRSA) and b-haemolytic streptococci (MIC90s:
0.12–0.5 mg/L), and also exhibits good overall activity against
penicillin-susceptible pneumococci, some enterococci, Listeria,
Legionella and Chlamydia. Iclaprim has moderate activity
against H. inﬂuenzae, M. catarrhalis and some Enterobacteria-
ceae [30]. Against Gram-positive pathogens, including MRSA,
iclaprim is rapidly bactericidal (Weiss et al., 18th ECCMID,
2008, Abstract P588) and has a post-antibiotic effect of
approximately 2–3 h (Hawser et al., 42nd ICAAC, 2002,
Abstract F-2029). Selection for resistance in vitro by serial
passage was found to be very difﬁcult (Hawser et al., 42nd
ICAAC, 2002, Abstract F-2028), suggesting a low bacterial
propensity for evolution towards iclaprim resistance.
Iclaprim can be administered intravenously or orally (oral
bioavailability is approximately 40%) and, together with lin-
ezolid, it is the only drug active against MDR Gram-positive
pathogens endowed with this interesting feature. Its half-life
is approximately 3 h. Iclaprim is metabolized by cytochromes
and glucuronidation, and elimination of metabolites is via the
urine (about two-thirds) and faeces (about one-third). Dos-
ing does not need adjustment in cases of mild-to-severe or
end-stage renal failure. No dose adjustment is needed in
cases of mild liver failure, whereas in cases of moderate liver
failure, a dose adjustment is indicated. The drug has a large
volume of distribution and can accumulate intracellularly,
suggesting that it could be used to treat infections caused by
intracellular pathogens that are susceptible to iclaprim
[30,31].
The clinical efﬁcacy of iclaprim has been investigated in
patients with cSSSIs. In phase II and phase III trials, intrave-
nous iclaprim (0.8 mg/kg twice daily) proved to be at least
as effective as vancomycin and non-inferior to linezolid,
respectively, as judged by clinical cure and microbiological
eradication rates, and safety and tolerability proﬁles were
overall very good [31] (Dryden et al., 18th ECCMID, 2008,
Abstract P545; Hadva´ry et al., 18th ECCMID, 2008,
Abstract P547; Jones et al., 18th ECCMID, 2008, Abstract
P550).
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